Intravenous naloxone plus transdermal buprenorphine in cancer pain associated with intractable cholestatic pruritus.
Marinangeli
Franco
F
Guetti
Cristiana
C
Angeletti
Chiara
C
Bonetti
Cristina
C
Paladini
Antonella
A
Piroli
Alba
A
Varrassi
Giustino
G
D000287:Administration, Topical; D000368:Aged; D000701:Analgesics, Opioid / Q000008:administration & dosage; D002047:Buprenorphine / Q000008:administration & dosage*; D002779:Cholestasis / Q000188:drug therapy* / Q000209:etiology; D002908:Chronic Disease; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D009270:Naloxone / Q000008:administration & dosage*; D009292:Narcotic Antagonists / Q000008:administration & dosage; D009369:Neoplasms / Q000150:complications* / Q000451:nursing; D010146:Pain / Q000209:etiology* / Q000517:prevention & control*; D010147:Pain Measurement / Q000187:drug effects; D010166:Palliative Care / Q000379:methods; D011537:Pruritus / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
D000701:Analgesics, Opioid; D004338:Drug Combinations; D009292:Narcotic Antagonists; D009270:Naloxone; D002047:Buprenorphine